MedTrace Logo

Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study

NCT07105228 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 290000

Last updated 2025-10-10

No results posted yet for this study

Summary

This study will describe and estimate the incidence of Retinal Vasculitis (RV) events among patients and patient eyes receiving aflibercept intravitreal (IVT) (Eylea®, aflibercept 2mg) therapy in US clinical practice.

The main objective is to describe demographic and clinical characteristics of patients receiving aflibercept 2mg injections, to estimate the incidence of RV and RV plus Intraocular Inflammation (IOI) following aflibercept 2mg injections and to describe characteristics of RV cases.

Conditions

  • Retinal Vasculitis

Interventions

DRUG

aflibercept 2mg

No study-specific interventions administered in this observational study

Sponsors & Collaborators

Principal Investigators

  • Clinical Trial Management · Regeneron Pharmaceuticals

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-15
Primary Completion
2025-08-30
Completion
2025-09-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07105228 on ClinicalTrials.gov